静脉曲张出血的药理预防。新发展

Joan Carles García-Pagán MD (Staff Member), Jaume Bosch MD (Professor of Medicine)
{"title":"静脉曲张出血的药理预防。新发展","authors":"Joan Carles García-Pagán MD (Staff Member),&nbsp;Jaume Bosch MD (Professor of Medicine)","doi":"10.1016/S0950-3528(97)90040-3","DOIUrl":null,"url":null,"abstract":"<div><p>The introduction of pharmacological therapy has been one of the major advances in the treatment of the complications of portal hypertension. Many drugs have been shown to reduce portal hypertension in patients with cirrhosis. However, the most widely used drugs and the only ones for which there is sufficient evidence, are the beta-blockers. These drugs have been, up to now, the only accepted prophylactic therapy for oesophageal variceal bleeding and are also an alternative treatment to sclerotherapy or surgery to prevent variceal rebleeding. A reduction in portal pressure gradient by beta-blockers below 12 mmHg or by more than 20% of baseline values is associated with almost a total protection from oesophageal bleeding. Such a marked response in portal pressure is only achieved in some patients receiving propranolol. New pharmacological approaches with a greater portal pressure reducing effect may improve the beneficial effect of drugs in preventing variceal bleeding. The more promising approach is the combined administration of beta-blockers and isosorbide-5-mononitrate, which has been shown to potentiate the reduction in portal pressure and to be highly effective in initial randomized clinical trials.</p></div>","PeriodicalId":77028,"journal":{"name":"Bailliere's clinical gastroenterology","volume":"11 2","pages":"Pages 271-287"},"PeriodicalIF":0.0000,"publicationDate":"1997-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3528(97)90040-3","citationCount":"6","resultStr":"{\"title\":\"5 Pharmacological prevention of variceal bleeding. New developments\",\"authors\":\"Joan Carles García-Pagán MD (Staff Member),&nbsp;Jaume Bosch MD (Professor of Medicine)\",\"doi\":\"10.1016/S0950-3528(97)90040-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The introduction of pharmacological therapy has been one of the major advances in the treatment of the complications of portal hypertension. Many drugs have been shown to reduce portal hypertension in patients with cirrhosis. However, the most widely used drugs and the only ones for which there is sufficient evidence, are the beta-blockers. These drugs have been, up to now, the only accepted prophylactic therapy for oesophageal variceal bleeding and are also an alternative treatment to sclerotherapy or surgery to prevent variceal rebleeding. A reduction in portal pressure gradient by beta-blockers below 12 mmHg or by more than 20% of baseline values is associated with almost a total protection from oesophageal bleeding. Such a marked response in portal pressure is only achieved in some patients receiving propranolol. New pharmacological approaches with a greater portal pressure reducing effect may improve the beneficial effect of drugs in preventing variceal bleeding. The more promising approach is the combined administration of beta-blockers and isosorbide-5-mononitrate, which has been shown to potentiate the reduction in portal pressure and to be highly effective in initial randomized clinical trials.</p></div>\",\"PeriodicalId\":77028,\"journal\":{\"name\":\"Bailliere's clinical gastroenterology\",\"volume\":\"11 2\",\"pages\":\"Pages 271-287\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0950-3528(97)90040-3\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bailliere's clinical gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0950352897900403\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950352897900403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

药物治疗的引入是门静脉高压症并发症治疗的主要进展之一。许多药物已被证明可以降低肝硬化患者的门静脉高压。然而,最广泛使用的药物和唯一有充分证据的药物是-受体阻滞剂。到目前为止,这些药物是唯一被接受的预防食管静脉曲张出血的治疗方法,也是硬化治疗或手术预防静脉曲张再出血的替代治疗方法。使用-受体阻滞剂将门静脉压力梯度降低至12 mmHg以下或降低基线值的20%以上,几乎可以完全防止食管出血。只有在一些服用心得安的患者中,门静脉压力才有如此明显的缓解。新的药理学方法具有更大的门静脉减压作用,可以提高药物预防静脉曲张出血的有益作用。更有希望的方法是联合使用-受体阻滞剂和异山梨酯-5-单硝酸酯,这已经被证明可以增强门静脉压力的降低,并且在最初的随机临床试验中非常有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
5 Pharmacological prevention of variceal bleeding. New developments

The introduction of pharmacological therapy has been one of the major advances in the treatment of the complications of portal hypertension. Many drugs have been shown to reduce portal hypertension in patients with cirrhosis. However, the most widely used drugs and the only ones for which there is sufficient evidence, are the beta-blockers. These drugs have been, up to now, the only accepted prophylactic therapy for oesophageal variceal bleeding and are also an alternative treatment to sclerotherapy or surgery to prevent variceal rebleeding. A reduction in portal pressure gradient by beta-blockers below 12 mmHg or by more than 20% of baseline values is associated with almost a total protection from oesophageal bleeding. Such a marked response in portal pressure is only achieved in some patients receiving propranolol. New pharmacological approaches with a greater portal pressure reducing effect may improve the beneficial effect of drugs in preventing variceal bleeding. The more promising approach is the combined administration of beta-blockers and isosorbide-5-mononitrate, which has been shown to potentiate the reduction in portal pressure and to be highly effective in initial randomized clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信